Effective Cancer Therapy with the $\alpha$-Particle Emitter $^{211}\text{At}$ Astatine in a Mouse Model of Genetically Modified Sodium/Iodide Symporter–Expressing Tumors


Abstract

Purpose: The sodium/iodide symporter (NIS) gene is currently explored in several trials to eradicate experimental cancer with radiodine ($^{131}$I) by its $\beta$-emission. We recently characterized NIS-specific cellular uptake of an alternative halide, radioastatine ($^{211}$At), which emits high-energy $\alpha$-particles. The aim of this study was to investigate in vivo effects of the high linear energy transfer (LET) emitter $^{211}$At on tumor growth and outcome in nude mice.

Experimental Design: We administered radioastatide in a fractionated therapy scheme to NMRI nude mice harboring rapidly growing solid tumors established from a papillary thyroid carcinoma cell line genetically modified to express NIS (K1-NIS). Animals were observed over 1 year. Tumor growth, body weight, blood counts, survival, and side effects were measured compared with control groups without therapy and/or lack of NIS expression.

Results: Within 3 months, radioastatide caused complete primary tumor eradication in all cases of K1-NIS tumor-bearing nude mice ($n = 25$) with no tumor recurrence during 1 year follow-up. Survival rates of the K1-NIS/$^{211}$At group were 96% after 6 months and 60% after 1 year, in contrast to those of control groups (maximum survival 40 days).

Conclusion: Our study indicates that $^{211}$At represents a promising substrate for NIS-mediated therapy of various cancers either with endogenous or gene transfer-mediated NIS expression.

Sodium/iodide symporter (NIS)–mediated iodide uptake into thyroid follicular cells is an essential step in thyroid hormone biosynthesis forming the basis for diagnosis and therapy of differentiated thyroid cancer with $\beta$-particle-emitting radiiodine, Na$^{131}$I (1, 2). Consistent with clinical findings, NIS is also functionally expressed in gastric mucosa, salivary gland, and lactating mammary gland, in addition to several other tissues that contain NIS mRNA and protein (3, 4). These nonthyroid tissues may be affected by NIS-mediated radionuclide transport but have much lower retention compared with healthy or differentiated cancerous thyroid tissue. Recently, functional NIS expression in breast carcinoma was described in a subgroup of patients; therefore, NIS-mediated radiiodide therapy has been suggested as a future treatment option for such patients (3, 5).

For nonthyroid cancers, the combination of NIS gene transfer and radioiodide administration offers an intriguing potential therapeutic approach. Experimental studies in various cancer models indicate that, in general, NIS gene transfer leads to radioiodide uptake capacity, but in the absence of cellular mechanisms leading to covalent iodide fixation radioactivity is rapidly lost, e.g., by diffusion through anion channels, limiting intratumoral radiation doses (4, 6–9). Although a variety of studies using $^{131}$I or other $\beta$-particle emitters (in part using NIS gene coupled to various tumor specific promoters) result in high cellular radioiodide uptake, only a few studies report tumoricidal effects in animal cancer models (4, 9–18).

$\alpha$-Particle-emitting radionuclides are attractive radiopharmaceuticals for targeted cancer therapy, as $\alpha$-particles are extremely cytotoxic due to their high LET ($\sim 100$ keV/$\mu$m) and potentially highly specific due to their short particle path of a few cell diameters (40-80 $\mu$m). But taking into account chemical and biochemical properties, physical half-life, decay schemes, and availability, one may consider only a few $\alpha$-particle emitters, including $^{211}$At, $^{212}$Bi, $^{212}$Bi, and $^{225}$Ac, as realistic candidates for therapeutic applications (19–21). Previously, we characterized the transport kinetics of the halide, $^{211}$Atastatide, by NIS, which are similar to those of its chemical relative, iodide (22). $^{211}$AtAstatide has a short half-life of 7.2 hours compatible with the relatively short residence times observed in cells transfected with NIS gene and unable to synthesize iodine-organic compounds. Furthermore, based on former dose calculations, we suggested that NIS-mediated tumor therapy using the $\alpha$-emitter $^{211}$At might be feasible in a xenograft mouse.

Authors’ Affiliations: 1Klinik für Nuklearmedizin, Medizinische Hochschule Hannover, Hanover, Germany; 2Institut für Pathologie, GSF-Forschungszentrum für Umwelt und Gesundheit, Neuherberg, Germany

Received 7/22/05; revised 11/18/05; accepted 11/30/05.

Grant support: HILF program of the Medizinische Hochschule Hannover, Germany.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Eyck Pötter, Department of Nuclear Medicine, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. E-mail: eyck.potter@web.de.

© 2006 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-05-1576
model. Here, we report our results of a first long-term follow-up animal study using [211At]astatide therapy with respect to tumor ablation, survival, and side effects.

Materials and Methods

Production of astatine. [211At] was produced in our cyclotron (MC35, Scanditronix, Uppsala, Sweden) according to the $^{209}$Bi($\alpha$,2n) $^{211}$At reaction by irradiation of a natural bismuth metal targets with up to 8 $\mu$A of 24.5 MeV $\alpha$-particles on target for 30 to 90 minutes. $^{211}$At was separated from the target by dry distillation at 650°C to 750°C for 30 to 60 minutes in a customized apparatus, collected in 0.02 mol/L Na$_2$SO$_3$ to stabilize the $^{211}$At– anion and used for experimentation after appropriate dilution as described before (22, 23).

Animals. All animal experiments were done according to German federal laws and the Institutional Animal Care and Use Committee guidelines of the Medizinische Hochschule Hannover. Animals were maintained under pathogen-free conditions with free access to water and standard rodent chow without using thyroid hormone blocking protocols. As previously described (22), we used xenografts of a human papillary thyroid carcinoma cell line, K1 (European Collection of Animal Cell Cultures, Salisbury, United Kingdom), lacking endogenous NIS genetically modified to express NIS under control of the cytomegalovirus promoter (K1-NIS) and of control cells. Tumors were raised in NMRI-nu/nunude mice aged 3 to 4 weeks by s.c. injection into the right or left flanks of 3 x 10$^6$ cells in 0.1 mL PBS. Over a growth phase of 2 to 4 weeks, tumors were allowed to reach volumes of 0.2 to 1.0 mL (measured by caliper rule). Mice ($n=25$) then received i.p. injections of 1.0, 0.5, and 1.0 MBq $^{211}$At on days 0, 5, and 16, respectively. We used three control groups: (a) NMRI nude mice given the same $^{211}$At therapy regimen but with tumors raised from mock-transfected K1 cells lacking NIS expression (K1-pCI, $n=5$), and NMRI nude mice with (b) K1-NIS tumors ($n=6$), or (c) K1-pCI tumors ($n=4$) were not given $^{211}$At.

In vitro uptake of astatide. As previously described, cellular $^{211}$At uptake (1 hour steady-state) was measured in K1-NIS cells and in NIS-negative K1-pCI cells as controls compared with uptake by the well-known NIS-specific inhibitor, NaClO$_4$ (22). Assays were done in triplicate; results are expressed as mean ± SD ($n=4$). We showed before that K1 wild-type cells lack both endogenous NIS expression and accumulation of iodide and astatide. We also showed that K1-NIS cells had same fast washout kinetics of accumulated radionuclides as other NIS-transfected nonthyroid carcinoma cells (22). Other authors showed that K1 cells did not express other thyroid-specific genes (e.g., thyroid peroxidase, TSH receptor; ref. 24 and references therein). Thus, K1 may be regarded for the purpose of this study as a suitable model for de-differentiated thyroid cancer.

Therapy follow-up. In all animal groups, we measured tumor size and body weight and photographed each individual every week. Animals were sacrificed when tumors exceeded sizes of 20 mm or body weight and photographed each individual every week. Histology. K1-NIS/211At mice were analyzed for therapy side effects or residual tumor tissue by histology compared with normal animals. Therefore, mice were killed at the end of the observation period (maximum of 1 year) and prepared for transport to GSF-Forschungszentrum (Neuherberg, Germany) by formalin fixation. In GSF, organs were removed and embedded in paraffin. Microscopic analysis for pathologic changes was done with H&E-stained sections of all organs. Biodistribution. To determine the in vivo distribution of $^{211}$At, K1-NIS solid tumor-bearing nude mice ($n=6$, tumor sizes, 0.2-0.7 mL) were killed 2 hours after i.p. injection of 1.3 to 1.8 MBq $^{211}$At. Organs were removed, weighed, and their radioactivity was determined. Results are expressed as percentage of injected dose per gram of tissue. Statistics. Survival analysis was done according to Kaplan-Meier using SPSS Software and log-rank test for comparisons between therapy groups. Paired and grouped t tests were used for cellular astatine uptake, biodistribution, and body weight. Variant analysis using Scheffe’s procedure was used for blood values. $P < 0.05$ were considered to indicate significant differences.

Results

In vitro cellular $^{211}$At uptake and biodistribution. In vitro, cellular $^{211}$At uptake was high only in K1-NIS cells and could specifically be blocked by 150 μmol/L NaClO$_4$, a known competitive inhibitor of NIS-mediated transport (Fig. 1A). In the mouse model, biodistribution experiments showed the highest uptake of $^{211}$At in K1-NIS tumor tissue, followed by the neck (including the thyroid), lung, stomach, and spleen (Fig. 1B). Therapy, follow-up, and survival. In a preliminary dose-finding study (data not shown), we used $^{211}$At and $^{211}$At in NMRI nude mice bearing K1-NIS tumors (25). Compared with controls without therapy (tumor = 3), an initial retardation of tumor growth for 5 weeks followed by rapid growth of the tumor were observed after $^{211}$At administration (25 MBq, n = 3). However,

---

Fig. 1. In vitro and in vivo specific $^{211}$At uptake. A, in vitro, cellular $^{211}$At uptake (1 hour steady-state, white columns) is high in K1-NIS cells but not in NIS-negative K1-pCI cells ($P < 0.0001$, grouped t test) and is suppressed by the NIS inhibitor NaClO$_4$ (black columns, $P < 0.0001$, grouped t test; mean $n=6$, tumor size, 0.2-0.7 mL). B, biodistribution of $^{211}$At in K1-NIS solid tumor-bearing nude mice after organ removal 2 hours after i.p. injection of $^{211}$At expressed as percentage of injected dose per gram of tissue. K1-NIS tumors significantly take up more $^{211}$At compared with other tissues ($P < 0.005$, paired t test and $P < 0.01$ Bonferroni t test).
radioastatine (1 MBq, \( n = 3 \)) caused tumor shrinkage followed by stable disease up to 8 weeks but then tumor regrowth started (25). A higher activity of \(^{131}I\) was used as dose calculations indicated 15- to 20-fold higher radiation dose per administered radioactivity of \(^{211}At\) compared with \(^{131}I\) (22).

The preliminary study mentioned above indicated insufficient dose for tumor elimination; thus, we developed a fractionated \(^{211}At\) therapy scheme (see Materials and Methods) allowing for higher dose delivery. After \(^{211}At\) administration (2.5 MBq total applied activity) according to that scheme, K1-NIS tumors showed complete remission (examples in Fig. 2A) within 90 days, without recurrence in the observation period, whereas controls had rapid tumor growth with a maximum survival of 40 days (Fig. 2B-E). The survival rate of K1-NIS/\(^{211}At\) mice (96%/60% at 6/12 months) was significantly higher than that of control groups (\( P < 0.0001 \), log-rank test; Fig. 3A). After \(^{211}At\) therapy, all K1-NIS mice had normal social and feeding behavior without diarrhea or obstipation or major hypothyroid symptoms. Body weights of K1-NIS mice increased after \(^{211}At\) treatment; in contrast, body weights of controls decreased due to cachexia necessitating sacrifice (Fig. 4). All measured blood counts in K1-NIS/\(^{211}At\) mice were within reference ranges for NMRI nude mice (Fig. 5). No significant signs for bone marrow depression except slight changes in hemoglobin concentration were determined in the peripheral blood. Also, no general clinical signs (i.e., petechial bleeding or lethargy) were evident.

**Monitoring in vivo tumor growth by scintigraphy.** Scintigraphy showed high \(^{99m}TcO_4^-\) uptake in K1-NIS tumors in untreated controls (Fig. 3B), but no tumor-specific uptake in K1-NIS/\(^{211}At\) mice 7 months after therapy due to complete tumor remission (Fig. 3C). However, thyroid function determined by radionuclide uptake was decreased to different levels in the K1-NIS/\(^{211}At\) mice indicating thyroid damage.

**Histology and side effects after \(^{211}At\) therapy.** Histologic findings (\( n = 23 \); Fig. 6) showed no tumor residues at the primary tumor site in 21 of 23 K1-NIS/\(^{211}At\) mice. Two K1-NIS/\(^{211}At\) mice had microscopic tumor residues at that site without proliferation, and an additional mouse had a microscopic local i.m. residual tumor node without proliferation or tumor invasion. Other histopathologic findings included effects on the thyroid (atrophy in all mice), liver [foci of atypical hepatocytes (\( n = 11 \)), adenoma (\( n = 2 \)), and differentiated carcinoma (\( n = 4 \))], spleen (increased erythropoiesis, \( n = 7 \)), lung (inflammation, \( n = 6 \)), stomach/bowel...
inflammation \((n = 5)\), hyperplasia \((n = 5)\), atypical cells \((n = 4)\), and papillomas \((n = 2)\)\], and skin (angiosarcoma, \(n = 4)\). One mouse had acute myeloid leukemia; another had an ovarian granulosa cell tumor.

**Discussion**

Here, we exploited the limited ion selectivity of NIS and a special feature of the \(\alpha\)-emitter \(^{211}\)At, its biochemical similarity to iodine, for direct delivery of radiotherapy into NIS-expressing tumors. In cellular models, we and others have shown before that \([^{211}\)At]astatide is actively transported across the plasma membrane into the cytoplasm by NIS (22, 26, 27). Consistent with these data, we showed in the present study high tumor uptake of \(^{211}\)At in the presence of NIS expression in a mouse model of thyroid carcinoma, whereas control cells transfected with empty vectors were unable to specifically accumulate the radionuclide. A total activity of 2.5 MBq \(^{211}\)At (100 kBq/g body weight; mean body weight 25 g) given in three fractions eliminated advanced NIS tumors in all animals and resulted in a significantly improved survival relative to untreated controls. In the K1-NIS/\(^{211}\)At group, no animal died from tumor progression. We are not aware of experimental studies using NIS in combination with radionuclide therapy reporting a comparable complete tumor elimination coupled to high survival with follow-up over 1 year. The mortality rates in our mice given high-dose \(^{211}\)At treatment are in accordance with reported LD\(_{10}\) values (dose killing 10% of healthy animals per year) in \(^{211}\)At dose escalation studies in B6C3F1 and BALB/c (nu/nu) mice (28).

Fig. 3. Survival and therapy monitoring after \(^{211}\)At therapy. A, survival of K1-NIS tumor-bearing nude mice \((n = 25)\) after \(^{211}\)At therapy and of control groups, K1-pCI tumor \((n = 4)\), K1-pCI tumor with \(^{211}\)At therapy \((n = 5)\), and K1-NIS tumor without \(^{211}\)At therapy \((n = 6)\). K1-NIS mice receiving \(^{211}\)At therapy had significant prolonged survival compared with controls \((P < 0.0001, \text{log-rank test})\). Planar scintigraphy of K1-NIS tumor-bearing nude mice before (mice 1-3, B) and 7 months after \(^{211}\)At therapy (mice 1-5; plus two additional untreated control parental mice (ctrl) C) obtained after 10 MBq \(^{99m}\)TcO\(_4^-\); 1 hour i.p. Tumor (tu) is located in right flank (B). Seven months posttreatment, scintigraphy shows no evidence of local disease; however, mouse 3 shows strongly decreased thyroid uptake (C). Physiologic uptake is apparent in thyroid (thy), stomach (sto), and bladder (bla) viewed from the ventral side.
Regarding side effects of $^{211}$At therapy, histopathology revealed normal tissue damage and secondary tumors in some animals in our study 6 to 12 months after therapy onset. Thyroid atrophy as found in all animals can be explained by physiologic NIS expression and NIS-dependent $^{211}$At uptake of thyrocytes. The secondary tumor spectrum we observed may have several causes. One possibility is that $^{211}$At induced carcinogenesis; as in other studies, various tumors have been found after injection of comparable amounts per gram body weight of $^{211}$At in mice but tumor incidence was not significantly elevated compared with aging control mice (28, 29). To our knowledge, there are only scant specific data available about tumor diseases in the derived athymic NMRI-nu/nu nude mice strain that we used. In one study, no tumor growth within 7 months was reported, but all animals in the study died after a maximum survival of 7 months due to inflammation of the colon (30). There is no further study available describing tumor incidence after a time period of >7 months. However, the background NMRI mouse strain spontaneously develops diverse tumors of lung, liver, ovary, and hematopoetic system with increasing age (31). Under the assumption that NMRI nude mice like the NMRI strain are prone to a certain tumor spectrum on aging (i.e. without any therapeutic intervention), it is likely that some late tumors we observed in surviving animals are not due to $^{211}$At therapy. But solving this question would require to examine a great number (>100) of animals for pathologic changes what is beyond the scope of this study. Here, we only observed a small control group without At therapy ($n=6$) for measurement of body weight over 1 year. No tumors were macroscopically evident but these mice were not examined by histology.

Whether direct $^{211}$At toxicity to normal tissue by specific (e.g., thyroid) or unspecific absorption (e.g., liver, skin, and ovary) or possible indirect toxicity caused by $^{211}$At-mediated thyroid dysfunction is responsible for side effects has to be clarified in further dose escalation studies using $^{211}$At in combination with T4-mediated TSH suppression to decrease TSH-dependent NIS expression in the thyroid and hypothyroidism. Furthermore, the efficacy of low-dose $^{211}$At regimens needs to be examined to optimize the relation of survival and side effects. With respect to conceivable $^{211}$At therapy in humans, such low-dose regimens may improve efficacy of radionuclide therapy of thyroid carcinomas or its metastases in which $^{131}$I uptake is detectable but insufficient for tumor eradication.

Although side effects are documented here, the therapeutic effect increases survival significantly. In other animal studies...
with different NIS-expressing systems, using β-emitters such as $^{131}$I or $^{188}$Re, mostly tumor growth retardation or partial remission followed by tumor regrowth was measured (9, 11, 15, 16, 18, 32).

The high tumor toxicity in our results coupled to lack of acute side effects and to only moderate late side effects is most likely explainable by NIS-dependent effective cellular $^{211}$At-astatide accumulation resulting in a high probability of an intracellular α-decay with a short path length of the α-particle. Thereby, DNA-damaging effects of emitted high LET α-particles are enhanced by intracellular recoil effects of the emitting astatide nuclei. In addition, the extreme high LET of α-emitters and recoil effects of the intracellular/intranuclear decay compared with much lower LET of β-emitters causes significant higher damage of various cellular proteins in direct contact to sensitive cytoplasmic metabolic processes, which are irreplaceable for cell survival. It is assumed that as few as four α-particles traversing the nucleus are sufficient to eliminate a cell (33–35).

In our study, we used a tumor model with NIS over-expression that results in a high therapeutic outcome and relatively low side effects after systemic $^{211}$At administration. A few promising therapy studies using radiodine using viral vectors with tissue-specific promoters targeting NIS to tumor cells in animals have already been done in combination with $^{131}$I therapy (10, 32, 36–38). It may be worth to consider that use of $^{211}$At in these existing models may improve the results.

---

**Fig. 6.** Histologic findings in $^{211}$At-treated K1-NIS mice. Normal thyroid of controls (A and B) and organ histopathology 208 days (C–E) and 363 days (F–G) after $^{211}$At treatment. The thyroid glands, which were not protected by TSH-suppressive hormone therapy to down-regulate NIS expression, show atrophy in all (23 of 23) examined animals (C and D). All mice had scar tissue in the flanks with increased number of hemosiderin-laden macrophages explaining skin hyperpigmentation at the tumor implantation site. In 2 of 23 animals, microscopic deposits of residual tumor cells were detected (E) in scar tissue of the flank, without macroscopic tumor nodules. One animal had a stable 4 mm residual tumor in the flank (sacrificed 208 days after treatment, not shown). Alterations of the liver included adenoma (F; measured 208 days after treatment), hepatocarcinomas (measured 296–363 days after treatment), and granulomas (285 days after treatment). Additional histopathology included severe dysplasia of the epidermis (G) 208 to 363 days after treatment and severe inflammation of the colon with atypical regenerative changes (H).
However, it has been taken into account that up to now, in vivo gene therapy approaches and other cell targeting methods, e.g., labeled antibodies, do not have sufficient specificity to prevent all nontargeted tissues from side effects.

Another aspect of the attraction of astatine for prospective use in clinical settings is the short half-life (7.2 hours of $^{211}$At versus 8 days of $^{131}$I) and the short range of $\alpha$-particles that would make exposure to nonpatient personnel minimal. Provided that low-dose $^{211}$At regimens could be established to result in minimal side effects, therapy of goiter and hyperthyroidism (tissue with high endogenous $\text{NIS}$ expression) might also be feasible substituting radiodiode by radioastatide. In conclusion, the results of our proof-of-principle study underscore the potential of high LET $\alpha$-emitter $^{211}$At-astatide for cytoreductive NIS-mediated therapy of malignant tumors. $^{211}$At proved to have a high tumoricidal potential in NIS gene-transfected tumors without major side effects limiting survival in mice. Thus, apart from potential use in tumors with endogenous NIS expression, $^{211}$At seems attractive for further evaluation in targeted NIS-mediated cancer gene therapy studies.

Acknowledgments

We thank H. Geerlings (Institute of Biometry, Medizinische Hochschule Hannover, Hannover, Germany) for help with statistical analysis.

References

Effective cancer therapy with the alpha-particle emitter [211At]astatine in a mouse model of genetically modified sodium/iodide symporter-expressing tumors.

Thorsten Petrich, Leticia Quintanilla-Martinez, Zekiye Korkmaz, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/12/4/1342

Cited articles
This article cites 38 articles, 13 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/12/4/1342.full.html#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
/content/12/4/1342#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.